Pfizer Ventures

Pfizer Ventures

Pfizer Ventures, also known as Pfizer Venture Investments, is a venture capital firm founded in 2004. The firm is a subsidiary of Pfizer. It is based in New York City, New York. As of March 2019, the firm has 45 active companies in its portfolio and has sold off its ownership in 58 companies. Its most recent investment is in Imara on March 2019, a company developing therapeutics for individuals with sickle cell diseases.

Funding

Pfizer Ventures focuses on funding companies in the field of bio-pharmaceuticals and neuroscience. The firm primarily seeks to fund companies that are based in the United States, although it also allocates 20% of its investments for non-U.S. companies. It finances companies at various stages, from early to growth. Since its conception, it has managed to collect $600 million from one funding round held in June 2018.

Timeline

Funded Companies

Company
Description
Website
Industry
Location

A protein analysis company developing products and systems to analyze protein

Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells

4D Molecular Therapeutics designs, develops and commercializes products for gene therapy.

Arkuda Therapeutics is a Cambridge, Massachusetts-based company.

NeuMoDx Molecular is an Ann Arbor, Michigan-based company.

Palleon Pharmaceuticals is a Waltham, Massachusetts-based company.

9 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Barbara Dalton

Vice President/Senior Managing Partner

Bill Burkoth

Senior Director

Denis Patrick

Vice President/Managing Partner

Elaine Jones

Vice President/Senior Partner

Laszlo Kiss

Principal/Executive Director

William Burkoth

Executive Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

4D Molecular Therapeutics

Artios Pharma

Biodesy

Imara

Kymera Therapeutics

Nimbus Therapeutics

System1 Biosciences

News

Title
Author
Date
Publisher
Description
FinSMEs
July 6, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Nick Paul
May 15, 2020
FierceBiotech
Johnson & Johnson has formed a collaboration with Lava Therapeutics to develop gamma-delta T-cell engagers. The agreement moves J&J into an emerging corner of the immuno-oncology sector that has attracted the interest of companies including Pfizer Ventures and Takeda.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.